Skip to content
Orahn Preiss-Bloom, Founder and Chief Innovation Officer

Orahn Preiss-Bloom, Founder and Chief Innovation Officer

Orahn is the Founder and Chief Innovation Officer at OSSIO. Previously, as founder and COO/CTO of LifeBond, Orahn developed two biosurgical product families to commercial stage and raised $60M, including from Johnson & Johnson Development Corporation. Prior, he was a biomechanics researcher at IDF Institute for Military Physiology and at Columbia University NY, Dept. of Orthopedic Surgery. Orahn has an M.Sc. in biomedical engineering from the Technion, Israel Institute of Technology.

Compression Screw Performance in a Load-Bearing In Vivo Model

The objective of this study was to evaluate the performance and mechanical integrity of theOSSIOfiber® Compression Screw in a full load-bearing osteotomy fixation in an ovine model through 6 months.   Key Takeaways: Histopathology results at 6 months indicated absence of callus formation, representing healing by first intention, was indicative of a very stable construct,Continue reading “Compression Screw Performance in a Load-Bearing In Vivo Model”

First-in-Human, Prospective, Multicenter Clinical Study

OSSIO is thrilled to announce the publication of our prospective, multicenter, first-in-human clinical trial in Foot & Ankle Orthopaedics.  Prospective, Multicenter, Clinical and Radiographic Evaluation of a Biointegrative, Fiber-Reinforced Implant for Proximal Interphalangeal Joint ArthrodesisLuke D. Cicchinelli, DPM, Jurij Štalc, MD, Martinus Richter, MD, PhD, Stuart Miller, MD Twenty-five patients underwent PIPJ fusions with OSSIOfiber HammertoeContinue reading “First-in-Human, Prospective, Multicenter Clinical Study”

White Paper on OSSIOfiber Technology

Our proprietary material technology, OSSIOfiber® Intelligent Bone Regeneration Technology, has unique material composition and structural design that contribute to its strength and optimal bio-integration for orthopedic fixation. Scientific and clinical leaders at OSSIO discuss the science behind OSSIOfiber in this Technology Overview White Paper.  Key Takeaways: Through the material composition and internal architecture, OSSIOfiber isContinue reading “White Paper on OSSIOfiber Technology”

In Vivo Study of Bio-Integrative OSSIOfiber Plates

The performance and bio-integration of the OSSIOfiber® Intelligent Bone Regeneration Technology has been successfully evaluated for in-bone and soft tissue fixation. The purpose of this in vivo study was to further evaluate the OSSIOfiber® material properties when implanted over the surface of bone, for its bone-implant interface, local tissue response and full bio-integration profile. ThisContinue reading “In Vivo Study of Bio-Integrative OSSIOfiber Plates”

Interested in OSSIOfiber®?

Complete the form and an OSSIOfiber® Advisor will get in touch.

Customer Service

For product inquiries or purchasing questions contact 833-781-7373 or email info@ossio.io

Address

Commercial Headquarters
OSSIO Inc
300 Tradecenter Drive, Suite 3690
Woburn, MA, 01801

Science & Manufacturing Center

OSSIO Ltd.
8 HaTochen Street
Cesarea, Israel 3079861

OSSIOfiber® has been used by 1500+ surgeons across the US

Footnotes

1. Data on file at OSSIO 2. Clinical study data on file at OSSIO 3. Kaiser, P.B., Watkins, I., Riedel, M. D., Cronin, P., Briceno, J., Kron, J. Y. (2019). Implant Removal Matrix for the Foot and Ankle Orthopaedic Surgeon. Foot & Ankle Specialist, 12(1), 79-97. https://doi.org/10.1177/1938640018791015 4. Pre-clinical animal studies (in-bone implantation of OSSIOfiber® and PLDLA control in rabbit femurs). Data on File at OSSIO. 5.Haddad, S. F., Helm, M. M., Meath, B., Adams, C., Packianathan, N., & Uhl, R. (2019). Exploring the Incidence, Implications, and Relevance of Metal Allergy to Orthopaedic Surgeons. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 3(4), e023. https://doi.org/10.5435/JAAOSGlobal-D-19-00023